Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium tc-99m sodium pertechnetate (American Health Staffing Group)
- Development stage
- Approved
- Lead developer
- University of Alberta
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
CPERT is a sponsor/trial shorthand for **cyclotron-produced technetium tc-99m sodium pertechnetate**, a diagnostic radiopharmaceutical used for nuclear medicine imaging. In the cited Phase I thyroid cancer study, CPERT refers specifically to Tc-99m pertechnetate manufactured by a cyclotron-based production process and evaluated for safety and comparability against conventional generator-produced Tc-99m pertechnetate in post-thyroidectomy patients with well differentiated thyroid carcinoma prior to planned iodine-131 therapy. Mechanistically, pertechnetate is taken up by tissues expressing the sodium-iodide symporter, enabling gamma-camera imaging of residual or functioning thyroid tissue rather than exerting a therapeutic effect.
- Other names
- cyclotron-produced Tc-99m pertechnetatecyclotron-produced technetium tc-99m sodium pertechnetateTc-99m pertechnetateTc99m pertechnetateTc 99m pertechnetate99mTc-pertechnetatesodium pertechnetate Tc-99m
02
Targets
NIS (Human sodium iodide symporter)
Beyond the preview
Go deeper on technetium tc-99m sodium pertechnetate (American Health Staffing Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium tc-99m sodium pertechnetate (American Health Staffing Group).